Quantcast

Latest Laval Stories

2010-11-12 06:20:00

LAVAL, QC, Nov. 12 /PRNewswire/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that on November 11, 2010 it received notice from Actavis South Atlantic LLC advising that Actavis has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval to market 150 and 300 mg generic versions of OLEPTRO(TM) (trazodone hydrochloride extended-release 150 and 300 mg tablets) in the United States. Under the Drug Price Competition...

2010-11-11 06:23:00

- Company's Second Product Launched in U.S., Third Product Approved in Europe - LAVAL, QC, Nov. 11 /PRNewswire-FirstCall/ -Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today reported its financial results for the third quarter and first nine months ended September 30, 2010.  All figures are in Canadian dollars unless otherwise stated. "Labopharm now has two products commercially available in the U.S. and our third - a twice-daily tramadol/acetaminophen product - is poised for...

2010-11-04 17:57:08

A team of Universit© Laval and Danisco researchers has just unlocked the secret of bacteria's immune system. The details of the discovery, which may eventually make it possible to prevent certain bacteria from developing resistance to antibiotics, are presented in today's issue of the scientific journal Nature. The team led by Professor Sylvain Moineau of Universit© Laval's Department of Biochemistry, Microbiology, and Bioinformatics showed that this mechanism, called CRISPR/Cas,...

2010-10-14 06:00:00

- Companies Establish Licensing and Distribution Agreements for Labopharm's INTELLITAB(TM)-Based Oxycodone-Acetaminophen and Twice-Daily Tramadol Acetaminophen - LAVAL, QC and MONTREAL, Oct. 14 /PRNewswire/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) and Paladin Labs Inc. (TSX:PLB) today announced they have expanded their commercial relationship through three licensing and distribution agreements under which Paladin will distribute two of Labopharm's products in certain jurisdictions. "Paladin...

2010-10-13 08:42:00

- National Marketing Authorizations Expected in Due Course/Marketing Partner Grunenthal Preparing to Launch in Multiple European Markets Late Next Year - LAVAL, QC, Oct. 13 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced its twice-daily tramadol-acetaminophen has received a positive opinion under the European Union Decentralized Procedure in eight countries (Czech Republic, Iceland, Ireland, Poland, Portugal, Slovakia, Slovenia and Spain). Marketing...

2010-08-12 06:00:00

- OLEPTRO(TM) Launched in the U.S. Market - LAVAL, QC, Aug. 12 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today reported its financial results for the second quarter and first six months ended June 30, 2010. All figures are in Canadian dollars unless otherwise stated. "The year to date is highlighted with a number of significant milestones, culminating with the U.S. launch of OLEPTRO(TM) earlier this week," said James R. Howard-Tripp, President and Chief Executive...

2010-05-05 06:00:00

- Angelini Labopharm Joint Venture to Launch OLEPTRO(TM) in Third Quarter of This Year - LAVAL, QC, May 5 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today reported its financial results for the first quarter 2010. All figures are in Canadian dollars unless otherwise stated. "With our joint venture with Angelini, we are well positioned for the U.S. launch of OLEPTRO(TM) in the third quarter of this year," said James R. Howard-Tripp, President and Chief Executive Officer,...

2010-03-25 14:55:18

Promising study published in the Journal of Biological Chemistry Canadian researchers have discovered a previously hidden channel to attack leukemia and other cancer cells, according to a new study published in the Journal of Biological Chemistry. The findings from the Universit© de Montr©al, Maisonneuve-Rosemont Hospital and Universit© Laval may change the way doctors treat cancer patients. "We found a gateway, which is present in all humans, that allows anti-cancer agents...

2010-02-25 06:00:00

- Company Preparing for Q3 2010 U.S. Launch of OLEPTRO(TM) - LAVAL, QC, Feb. 25 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2009. All figures are in Canadian dollars unless otherwise stated. "On February 2, Labopharm realized an important milestone - the FDA's approval of our once-daily antidepressant, OLEPTRO(TM), for the U.S. market," said James R. Howard-Tripp, President and...

0592c336d83904a73c6239c8f8e39a2d1
2010-02-17 08:30:00

The southern limit of permanently frozen ground, or permafrost, is now 130 kilometers further north than it was 50 years ago in the James Bay region, according to two researchers from the Department of Biology at Universit© Laval. In a recent issue of the scientific journal Permafrost and Periglacial Processes, Serge Payette and Simon Thibault suggest that, if the trend continues, permafrost in the region will completely disappear in the near future. The researchers measured the retreat...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related